novel targeted cancer treatments Archives -

News/ News/ News/ Oncology/ Sales and Marketing

Novartis bags FDA okay for BRAF-positive tumour combination

Phil Taylor BRAF, Mekinist, Novartis, novel targeted cancer treatments, Oncology, Tabrecta, Tafinlar 0 Comment

Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for

Novartis bags FDA okay for BRAF-positive tumour combination

https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/

News/ News/ Oncology

BMS sets up Roche, Pfizer rivalry with Turning Point takeover

Phil Taylor Bristol-Myers Squibb, M&A, novel targeted cancer treatments, Oncology, Turning Point Therapeutics 0 Comment

Bristol-Myers Squibb’s all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters

BMS sets up Roche, Pfizer rivalry with Turning Point takeover

https://pharmaphorum.com/news/bms-sets-up-roche-pfizer-rivalry-with-turning-point-takeover/

News/ News/ News/ Oncology/ R&D

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

Phil Taylor AbbVie, Haematology, myelofibrosis, navitoclax, novel targeted cancer treatments, Oncology, Venclexta 0 Comment

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

https://pharmaphorum.com/news/aacr-abbvie-says-mid-stage-trial-backs-navitoclax-in-myelofibrosis/

News/ News/ Oncology

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

Phil Taylor Amgen, KRAS, Lumakras, Mirati, Non-small cell lung cancer, Novartis, novel targeted cancer treatments, Oncology 0 Comment

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

https://pharmaphorum.com/news/aacr-novartis-joins-the-kras-clan-eyeing-swift-move-to-phase-3/

Market Access/ News/ News

FDA knocks back MEI’s plans for drug in troubled PI3K class

Phil Taylor fda, MEI Pharma, novel targeted cancer treatments, Oncology, PI3K 0 Comment

MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K

FDA knocks back MEI’s plans for drug in troubled PI3K class

https://pharmaphorum.com/news/fda-knocks-back-meis-plans-for-drug-in-troubled-pi3k-class/

News/ News/ Oncology

AZ, Scorpion strike deal on elusive transcription factor targets in cancer

Phil Taylor AstraZeneca, novel targeted cancer treatments, Oncology, partnering, Scorption Therapeutics, transcription factors 0 Comment

AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in

AZ, Scorpion strike deal on elusive transcription factor targets in cancer

https://pharmaphorum.com/news/az-scorpion-strike-deal-on-elusive-transcription-factor-targets-in-cancer/

News/ News/ Oncology

Kura hit as FDA slaps partial hold on leukaemia trial

Phil Taylor acute myeloid leukaemia, Kura Oncology, menin inhibitor, novel targeted cancer treatments, Oncology 0 Comment

Share in Kura Oncology have come under pressure after a patient death in a clinical trial of the

Kura hit as FDA slaps partial hold on leukaemia trial

https://pharmaphorum.com/news/kura-hit-as-fda-slaps-partial-hold-on-leukaemia-trial/

News/ News/ Oncology

Trial flop busts Deciphera’s blockbuster hopes for Qinlock

Phil Taylor Deciphera, GIST, novel targeted cancer treatments, Oncology, Qinlock 0 Comment

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of

Trial flop busts Deciphera’s blockbuster hopes for Qinlock

https://pharmaphorum.com/news/trial-flop-busts-decipheras-blockbuster-hopes-for-qinlock/

News/ News/ Oncology

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

Phil Taylor asciminib, chronic myeloid leukaemia, fda, Novartis, novel targeted cancer treatments, Oncology, regulatory approval, Scemblix 0 Comment

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

https://pharmaphorum.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia/

Trending

novel targeted cancer treatments

Login